Literature DB >> 28212061

PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma.

Guru Sonpavde1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28212061     DOI: 10.1056/NEJMe1701182

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

1.  Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.

Authors:  Guru Sonpavde; Juliane Manitz; Chen Gao; Darren Tayama; Constanze Kaiser; Daniel Hennessy; Doris Makari; Ashok Gupta; Shaad Essa Abdullah; Guenter Niegisch; Jonathan E Rosenberg; Dean F Bajorin; Petros Grivas; Andrea B Apolo; Robert Dreicer; Noah M Hahn; Matthew D Galsky; Andrea Necchi; Sandy Srinivas; Thomas Powles; Toni K Choueiri; Gregory R Pond
Journal:  J Urol       Date:  2020-06-18       Impact factor: 7.450

2.  Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

Authors:  Kyu Sang Lee; Kyoungyul Lee; Sumi Yun; Seyoung Moon; Yujun Park; Jung Ho Han; Chae-Yong Kim; Hye Seung Lee; Gheeyoung Choe
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

Review 3.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

4.  BORA regulates cell proliferation and migration in bladder cancer.

Authors:  Songtao Cheng; Tianchen Peng; Xiaolu Zhu; Fenfang Zhou; Gang Wang; Lingao Ju; Yu Xiao; Xuefeng Liu; Xinghuan Wang
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

5.  Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Authors:  Guru P Sonpavde; Luigi Mariani; Salvatore Lo Vullo; Daniele Raggi; Patrizia Giannatempo; Aristotle Bamias; Simon J Crabb; Joaquim Bellmunt; Evan Y Yu; Guenter Niegisch; Ulka N Vaishampayan; Christine Theodore; Dominik R Berthold; Sandy Srinivas; Srikala S Sridhar; Elizabeth R Plimack; Jonathan E Rosenberg; Thomas Powles; Matthew D Galsky; Andrea Necchi
Journal:  J Urol       Date:  2018-09-04       Impact factor: 7.450

Review 6.  Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder.

Authors:  E El Rassy; T Assi; Z Bakouny; N Pavlidis; J Kattan
Journal:  Clin Transl Oncol       Date:  2018-09-04       Impact factor: 3.405

7.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

Review 8.  Engineering chimeric antigen receptor-T cells for cancer treatment.

Authors:  Baixin Ye; Creed M Stary; Xuejun Li; Qingping Gao; Chunsheng Kang; Xiaoxing Xiong
Journal:  Mol Cancer       Date:  2018-02-15       Impact factor: 27.401

Review 9.  Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Authors:  Christiane Thallinger; Thorsten Füreder; Matthias Preusser; Gerwin Heller; Leonhard Müllauer; Christoph Höller; Helmut Prosch; Natalija Frank; Rafal Swierzewski; Walter Berger; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2017-11-02       Impact factor: 1.704

Review 10.  Pitfalls in the radiological response assessment of immunotherapy.

Authors:  Lucian Beer; Maximilian Hochmair; Helmut Prosch
Journal:  Memo       Date:  2018-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.